B
Bain Capital Life Sciences Investors, LLC
+ HoldingKLRA
+20.58%
3M Return
$16.410
+1.076 (+6.56%)Zum Schluss
Loading chart…
- High
- 17.060
- Open
- 15.210
- VWAP
- 16.21
- Vol
- 1.21M
- Mkt Cap
- —
- Low
- 15.150
- Amount
- 19.57M
- EV/EBITDA, TTM
- 0.00
Kailera Therapeutics, Inc. is a clinical-stage biotechnology company focused on obesity care. The Company is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for weight loss. Ribupatide injection is in global Phase III trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. The Company is developing a once-daily oral tablet formulation, ribupatide oral, to provide a convenient oral option with compelling weight loss among oral treatments. Additionally, it is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist.
AI analysis of Kailera Therapeutics Inc (KLRA)
holdKailera Therapeutics is currently not a strong buy due to recent negative performance and financial losses, but it has potential upside if its pipeline candidates succeed.
Bewertungskennzahlen
The current forward P/E ratio for Kailera Therapeutics Inc (KLRA) is 0.00, compared to its 5-year average forward P/E of .
Whales holding KLRA
Event-Zeitleiste
News
8.508-16FoolGLP-1 Market Growth: Biotech Companies Seize Opportunities
5.008-11NewsfilterKailera Appoints New Chief Technology Officer
8.507-22CNBCAmerican Biotech Firm Plans Hong Kong IPO
2.007-15FoolInvestment Opportunities in the Growing GLP-1 Market
8.507-15NASDAQ.COMNovo Nordisk and Kailera's Promising GLP-1 Drug Pipelines
KLRA FAQ — answered by Alphio AI
Kailera Therapeutics, Inc. is a clinical-stage biotechnology company focused on obesity care. The Company is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for weight loss. Ribupatide injection is in global Phase III trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. The Company is developing a once-daily oral tablet formulation, ribupatide oral, to provide a convenient oral option with compelling weight loss among oral treatments. Additionally, it is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. It operates in the Healthcare sector.
Kailera Therapeutics is currently not a strong buy due to recent negative performance and financial losses, but it has potential upside if its pipeline candidates succeed.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.